Most Popular

    MacTel Project 2021 Update

    MacTel Project 2021 Update

    LOWY MEDICAL RESEARCH INSTITUTE - LMRI This past year has surely been an interesting and challenging one.  We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges prese...

    The Latest MacTel Research: What does it mean for patients?

    The Latest MacTel Research: What does it mean for patients?

    Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2.  The article, “Serine and Lipid Metabolism in Macular Disease and...

    Results of NT-501 Phase 2 Study Published

    Results of NT-501 Phase 2 Study Published

    January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal o...

    Lowy Medical Research Institute scientists find cause of debilitating eye disease

    Lowy Medical Research Institute scientists find cause of debilitating eye disease

    15-year effort points to treatments to help MacTel patients and offers potential new insights into other eye diseases LA JOLLA, CA–September 11, 2019– Scientists at the Lowy Medical Research Institute (LMRI) have discovered one cause of a progre...

    Phase 3 Trial Currently Enrolling MacTel Patients

    Phase 3 Trial Currently Enrolling MacTel Patients

    In a collaboration with Neurotech Pharmaceuticals, the Lowy Medical Research Institute is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a multi-center...

    CNTF Phase 3 Trial Enrollment Complete

    CNTF Phase 3 Trial Enrollment Complete

    September 21, 2020 In a collaboration with Neurotech Pharmaceuticals, the Lowy Medical Research Institute is conducting a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a...